The global pharmacokinetics services market size was valued at USD 2.0 billion in 2025 and is projected to grow from USD 2.1 billion in 2026 to USD 3.6 billion in 2033, at a CAGR of 7.7% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 37.0% in 2025. Poor pharmacokinetics (PK) of therapeutics is one of the key reasons for higher drug attrition. To mitigate this challenge, researchers are integrating PK evaluations of novel molecular entities at every stage of the drug development stage.
Implementing predictive preclinical pharmacokinetics/ pharmacodynamics (PK/PD) models in various clinical trial stages is a promising way to address major bottlenecks in the pharmaceutical development process. This is primarily owing to PK studies identify potential challenges early and assist in required modifications and other development strategies to mitigate drug development challenges.
Increasing awareness among physicians, surgeons, and patients about the advantages of pharmacokinetic and toxicological studies to address various issues such as human equivalent doses and no observed effect levels services has boosted the market. Over the past decades, PK has gained significant prominence in drug discovery. Having understood the role of pharmacokinetics in pharmaceutical development, government and regulatory bodies are undertaking focused efforts to standardize pharmacokinetic protocols.
In the past years, regulatory requirements for clinical pharmacokinetic data have been progressively evolving to address the drug candidate's safety implications. PK study determines the initial amount of dosage that can be administered to study the therapeutic effects as well as potential side effects of the drug. This factor has played a vital role in reshaping this market. PK/PD analysis has helped progress drug development from preclinical studies to rapid and efficient in-man studies. The use of human in vivo and in vitro models for studying pharmacokinetics variability in the clinical development phase has been demonstrated for various pharmaceuticals. During drug development, phase I trials are the first opportunity to study the PK of a drug. They are performed on patients with cancer or healthy volunteers and are designed to determine an acceptable and safe dose for the later stages of clinical trials.
The gradual evolution of drug development into sound pharmacology has prompted several companies to broaden their service portfolio to maintain their competitive edge in the market. This is evident through the presence of a large number of companies with a broad service portfolio to serve various pharmaceutical development phases. Moreover, PK studies are interfacing with other drug discovery functions, such as toxicology, clinical pharmacology, and marketing. This interface has lucratively bolstered the adoption of PK services within the pharmaceutical industry. Certain limitations of in vitro PK studies, such as the inability of available experiments and protocols to predict complete interactions of target and drug candidate, are expected to hamper market growth during the forecast period.
▪ Canada
▪ Mexico
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
▪ China
▪ India
▪ Australia
▪ Thailand
▪ South Korea
▪ Argentina
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Implementing predictive preclinical pharmacokinetics/ pharmacodynamics (PK/PD) models in various clinical trial stages is a promising way to address major bottlenecks in the pharmaceutical development process. This is primarily owing to PK studies identify potential challenges early and assist in required modifications and other development strategies to mitigate drug development challenges.
Increasing awareness among physicians, surgeons, and patients about the advantages of pharmacokinetic and toxicological studies to address various issues such as human equivalent doses and no observed effect levels services has boosted the market. Over the past decades, PK has gained significant prominence in drug discovery. Having understood the role of pharmacokinetics in pharmaceutical development, government and regulatory bodies are undertaking focused efforts to standardize pharmacokinetic protocols.
In the past years, regulatory requirements for clinical pharmacokinetic data have been progressively evolving to address the drug candidate's safety implications. PK study determines the initial amount of dosage that can be administered to study the therapeutic effects as well as potential side effects of the drug. This factor has played a vital role in reshaping this market. PK/PD analysis has helped progress drug development from preclinical studies to rapid and efficient in-man studies. The use of human in vivo and in vitro models for studying pharmacokinetics variability in the clinical development phase has been demonstrated for various pharmaceuticals. During drug development, phase I trials are the first opportunity to study the PK of a drug. They are performed on patients with cancer or healthy volunteers and are designed to determine an acceptable and safe dose for the later stages of clinical trials.
The gradual evolution of drug development into sound pharmacology has prompted several companies to broaden their service portfolio to maintain their competitive edge in the market. This is evident through the presence of a large number of companies with a broad service portfolio to serve various pharmaceutical development phases. Moreover, PK studies are interfacing with other drug discovery functions, such as toxicology, clinical pharmacology, and marketing. This interface has lucratively bolstered the adoption of PK services within the pharmaceutical industry. Certain limitations of in vitro PK studies, such as the inability of available experiments and protocols to predict complete interactions of target and drug candidate, are expected to hamper market growth during the forecast period.
Global Pharmacokinetics Services Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global pharmacokinetics services market report based on application, drug type, end use, and region:Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
- Small Molecules
- Large Molecules (Biopharmaceuticals)
Application Outlook (Revenue, USD Billion, 2021 - 2033)
- Small and Medium Enterprise
- Large Enterprise
End Use Outlook (Revenue, USD Billion, 2021 - 2033)
- Biotechnology & Pharmaceutical Companies
- Academic & Government Research Institutes
- Others
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
▪ Canada
▪ Mexico
- Europe
▪ Germany
▪ France
▪ Italy
▪ Spain
▪ Denmark
▪ Sweden
▪ Norway
- Asia Pacific
▪ China
▪ India
▪ Australia
▪ Thailand
▪ South Korea
- Latin America
▪ Argentina
- Middle East and Africa
▪ Saudi Arabia
▪ UAE
▪ Kuwait
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Pharmacokinetic Services Market Variables, Trends & Scope
Chapter 4. Pharmacokinetic Services Market: Drug Type Estimates & Trend Analysis
Chapter 5. Pharmacokinetic Services Market: Application Estimates & Trend Analysis
Chapter 6. Pharmacokinetic Services Market: End Use Estimates & Trend Analysis
Chapter 7. Pharmacokinetic Services Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- Evotec SE
- Certara
- Pacific BioLabs, Inc
- Aragen Life Sciences Limited
- Medicilon USA Corporation
- Thermo Fisher Scientific Inc.
- Charles River Laboratories.
- Parexel International (MA) Corporation.
- Eurofins Discovery.
- Frontage Labs.
- SGS Société Générale de Surveillance SA.
- LGC Limited
- Creative Bioarray
